G

Genesis Molecular AI

AI-driven drug discovery platform for pharma

Machine Learning Research Engineer - Foundation Models

Full-Time
No salary listed
Mid, Senior, Expert
Master's, PhD
San Mateo, CA, USA+1 moreMore locations: New York, NY, USA
HybridThree days or fewer per week may be on-site under the hybrid arrangement.
AI & Machine LearningAI Research

About the job

Requirements
  • At least 2 years of industry experience building complex machine learning systems.
  • Deep expertise in building scalable, high-performance foundation models, pretraining, post-training methods, and related systems.
  • Experience writing clean, high-performance code across the machine learning stack, including Python, PyTorch, and distributed training systems.
  • Ability to design, optimize, and implement novel modeling approaches, with an understanding of the mathematics and systems behind modern machine learning methods.
  • Experience training models at scale with distributed training, large-scale datasets, and performance optimization across GPU clusters.
  • Hands-on experience writing CUDA kernels or optimizing GPU workloads beyond standard frameworks.
  • Hands-on experience with PyTorch, PyTorch Lightning, Ray Distributed Training, and PyTorch Geometric.
  • Ability to iterate on novel architectures, training pipelines, and experimental ideas while maintaining rigorous engineering discipline.
  • Ability to communicate and collaborate effectively with computational chemistry, structural biology, and medicinal chemistry scientists.
  • Curiosity and willingness to learn the intersection of artificial intelligence, physics, chemistry, and biology.
Responsibilities
  • Drive the research and development and scaling of foundation models, taking ownership of engineering and experimentation for key research initiatives.
  • Implement, optimize, and build novel foundation models from initial research prototypes to high-performance production models.
  • Optimize large-scale machine learning systems, including distributed training, inference efficiency, and GPU-level optimizations.
  • Engage with deep learning literature and build upon novel architectures and training methods to create new capabilities.
  • Bridge machine learning research and computational chemistry workflows with computational chemists, structural biologists, and medicinal chemists.
  • Productionize Pearl and related structure prediction models for deployment and integration into internal and partner drug discovery pipelines.
  • Design experimental plans, execute them on large-scale compute infrastructure, analyze results, and use findings to guide subsequent research cycles.
  • Ship state-of-the-art models to production.
  • Integrate models into the drug discovery platform through close collaboration with the broader team.
  • Mentor and guide other researchers and engineers.
  • Publish work and represent Genesis at artificial intelligence and machine learning conferences and workshops.
Desired Qualifications
  • Experience with novel research in LLMs, diffusion, reinforcement learning, or other cutting-edge generative or predictive machine learning models.
  • Experience with computational chemistry or drug discovery systems, especially protein-ligand structure prediction, small-molecule modeling, or computational drug discovery workflows.
  • Experience with diffusion models or other generative architectures applied to scientific or molecular problems.
  • Experience with LLM post-training techniques such as supervised fine-tuning, reinforcement learning from human feedback, synthetic data pipelines, or other post-training systems.
  • Experience with performance engineering using Triton kernels, TensorRT, quantization, or large-scale model serving.
  • Publications in top-tier machine learning venues such as NeurIPS, ICML, or ICLR.
  • Experience with PyTorch, PyTorch Lightning, Ray Distributed Training, PyTorch Geometric, or related systems.
  • An MS or PhD in machine learning, computer science, computational science, or equivalent research or engineering experience.

About the company

Genesis Molecular AI uses artificial intelligence to speed up drug discovery for the pharmaceutical industry. It combines 3D spatial graph modeling and advanced molecular simulation to generate and evaluate potential drug candidates and to uncover novel protein targets. The platform translates complex molecular data into actionable candidates by representing molecules in 3D graphs and running simulations to predict how they bind to target proteins, helping partners identify promising therapies. The company differentiates itself by integrating 3D spatial graph modeling with detailed molecular simulations to explore untapped chemical space and novel targets, and by focusing on business-to-business partnerships with pharma and biotech companies. Its goal is to accelerate drug discovery for partners by delivering AI-generated candidates and enabling faster progression from target to therapy.

Company Size

51-200

Company Stage

Late Stage VC

Total Funding

$400.1M

Headquarters

San Mateo, California

Founded

2019

Get referred to Genesis Molecular AI

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • May 2026 Incyte expansion delivered $120 million upfront, including $40 million equity.
  • Incyte will share proprietary data and fund compute, improving Genesis model training.
  • Genesis claims Pearl outperformed all cofolding models on OpenBind in October 2025.

What critics are saying

  • Incyte owns exclusive commercialization rights, limiting Genesis’s downstream capture through 2026.
  • OpenAI, Recursion, and Schrödinger intensify AI-drug-discovery competition for talent and partners.
  • If Pearl and GEMS miss wet-lab success, Genesis becomes a services vendor.

What makes Genesis Molecular AI unique

  • GEMS combines foundation models, physical simulation, and proprietary experimental data.
  • Genesis secured Incyte’s exclusive 2025 and expanded 2026 collaboration rights.
  • Sergey Edunov joined in December 2025 to scale foundation-model leadership.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Dental Insurance

Vision Insurance

401(k) Retirement Plan

Unlimited Paid Time Off

Parental Leave

Disability Insurance

Life Insurance

Growth & Insights and Company News

Headcount

6 month growth

3%

1 year growth

6%

2 year growth

7%
Business Wire
May 21st, 2026
Incyte and Genesis Expand Molecular AI Collaboration to Accelerate Drug Discovery

Incyte and Genesis expand molecular AI collaboration to accelerate 
drug discovery

Business News Today
Dec 3rd, 2025
Can Genesis Molecular AI leap ahead in biotech with Meta's Llama leader now onboard?

Can Genesis Molecular AI leap ahead in biotech with Meta's Llama leader now onboard? Genesis Molecular AI hires Meta's Llama leader Sergey Edunov to lead foundation models. Discover how this move strengthens its AI drug discovery platform. Genesis Molecular AI, the foundation model-driven drug design firm formerly known as Genesis Therapeutics, has appointed Sergey Edunov as Senior Vice President of Foundation Models. The executive hire marks a strategic inflection point as the company prepares to scale its GEMS platform and unveil new generative model research at the NeurIPS 2025 conference. Sergey Edunov is best known for his leadership role in developing Meta Platforms' Llama 2 and Llama 3 large language models. He brings over two decades of software engineering and AI research experience, having previously served as Senior Director of AI Research in Meta's generative AI division. His arrival at Genesis Molecular AI signals the firm's ambition to compete at the highest levels of foundation model development applied to molecular design.

Latest Nigerian News
Aug 7th, 2025
Genesis Therapeutics raises $52M for AI drug discovery

Genesis Therapeutics has successfully raised a $52 million A round to advance its AI-focused drug discovery mission. The company employs a novel simulation approach and a cross-disciplinary team to efficiently explore the vast array of potential medicinal molecules.

Today Media
May 28th, 2025
Incyte aims to accelerate drug research with AI collaboration

Earlier this year, Incyte inked a deal with Genesis Therapeutics to use the biotech company's AI platform to develop small molecule medicines.

Fierce Biotech
Feb 20th, 2025
Incyte pens $885M biobucks AI pact to use Genesis' GEMS to develop new drugs

Incyte is sticking to its strategy this year of finding "early-stage, exotic stuff" - paying Genesis Therapeutics $30 million upfront to use the biotech's artificial intelligence platform to develop small molecule medicines against undisclosed targets.